Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer

Kathryn E. Ware, Mariano Garcia-Blanco, Andrew J. Armstrong, Scott M. Dehm

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form, genetic and epigenetic adaptation, clonal selection, and evolution of the tumor micro-environment contribute to the emergence of unique biological characteristics under the selective pressureof external stresses. These stresses include the therapies appliedinthe clinic or laboratory and the exposures of cancers to hormonal, paracrine, or autocrine stimuli in the context of the tumormicro- andmacro-environment. The androgen receptor (AR) is a key gene involved in PCa etiology and oncogenesis, including disease development, progression, response to initial hormonal therapies, and subsequent resistance to hormonal therapies. Alterations in the AR signaling pathway have been observed in certain selection contexts and contribute to the resistance to agents that target hormonal regulation of the AR, including standard androgen deprivation therapy, antiandrogens such as enzalutamide, and androgen synthesis inhibitionwith abiraterone acetate.One such resistancemechanismis the synthesis of constitutively active AR variants lacking the canonical ligand-binding domain. This review focuses on the etiology, characterization, biological properties, and emerging data contributingto the clinical characteristicsofARvariants, andsuggests approaches to-full-length AR and AR variant biomarker validation, assessment, and systemic targeting in the clinic.

Original languageEnglish (US)
JournalEndocrine-Related Cancer
Volume21
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Castration
Androgen Receptors
Prostatic Neoplasms
Androgens
Clonal Evolution
Androgen Antagonists
Therapeutics
Epigenomics
Disease Progression
Neoplasms
Carcinogenesis
Biomarkers
Ligands
Genes

Keywords

  • Androgen receptor
  • AR variants
  • Castration resistant prostate cancer
  • Epithelial to mesenchymal transition
  • Metastasis
  • Splice variants

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Cite this

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. / Ware, Kathryn E.; Garcia-Blanco, Mariano; Armstrong, Andrew J.; Dehm, Scott M.

In: Endocrine-Related Cancer, Vol. 21, No. 4, 2014.

Research output: Contribution to journalArticle

@article{6dd330e0efde494390234c4ebf85b699,
title = "Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer",
abstract = "As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form, genetic and epigenetic adaptation, clonal selection, and evolution of the tumor micro-environment contribute to the emergence of unique biological characteristics under the selective pressureof external stresses. These stresses include the therapies appliedinthe clinic or laboratory and the exposures of cancers to hormonal, paracrine, or autocrine stimuli in the context of the tumormicro- andmacro-environment. The androgen receptor (AR) is a key gene involved in PCa etiology and oncogenesis, including disease development, progression, response to initial hormonal therapies, and subsequent resistance to hormonal therapies. Alterations in the AR signaling pathway have been observed in certain selection contexts and contribute to the resistance to agents that target hormonal regulation of the AR, including standard androgen deprivation therapy, antiandrogens such as enzalutamide, and androgen synthesis inhibitionwith abiraterone acetate.One such resistancemechanismis the synthesis of constitutively active AR variants lacking the canonical ligand-binding domain. This review focuses on the etiology, characterization, biological properties, and emerging data contributingto the clinical characteristicsofARvariants, andsuggests approaches to-full-length AR and AR variant biomarker validation, assessment, and systemic targeting in the clinic.",
keywords = "Androgen receptor, AR variants, Castration resistant prostate cancer, Epithelial to mesenchymal transition, Metastasis, Splice variants",
author = "Ware, {Kathryn E.} and Mariano Garcia-Blanco and Armstrong, {Andrew J.} and Dehm, {Scott M.}",
year = "2014",
doi = "10.1530/ERC-13-0470",
language = "English (US)",
volume = "21",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "4",

}

TY - JOUR

T1 - Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer

AU - Ware, Kathryn E.

AU - Garcia-Blanco, Mariano

AU - Armstrong, Andrew J.

AU - Dehm, Scott M.

PY - 2014

Y1 - 2014

N2 - As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form, genetic and epigenetic adaptation, clonal selection, and evolution of the tumor micro-environment contribute to the emergence of unique biological characteristics under the selective pressureof external stresses. These stresses include the therapies appliedinthe clinic or laboratory and the exposures of cancers to hormonal, paracrine, or autocrine stimuli in the context of the tumormicro- andmacro-environment. The androgen receptor (AR) is a key gene involved in PCa etiology and oncogenesis, including disease development, progression, response to initial hormonal therapies, and subsequent resistance to hormonal therapies. Alterations in the AR signaling pathway have been observed in certain selection contexts and contribute to the resistance to agents that target hormonal regulation of the AR, including standard androgen deprivation therapy, antiandrogens such as enzalutamide, and androgen synthesis inhibitionwith abiraterone acetate.One such resistancemechanismis the synthesis of constitutively active AR variants lacking the canonical ligand-binding domain. This review focuses on the etiology, characterization, biological properties, and emerging data contributingto the clinical characteristicsofARvariants, andsuggests approaches to-full-length AR and AR variant biomarker validation, assessment, and systemic targeting in the clinic.

AB - As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form, genetic and epigenetic adaptation, clonal selection, and evolution of the tumor micro-environment contribute to the emergence of unique biological characteristics under the selective pressureof external stresses. These stresses include the therapies appliedinthe clinic or laboratory and the exposures of cancers to hormonal, paracrine, or autocrine stimuli in the context of the tumormicro- andmacro-environment. The androgen receptor (AR) is a key gene involved in PCa etiology and oncogenesis, including disease development, progression, response to initial hormonal therapies, and subsequent resistance to hormonal therapies. Alterations in the AR signaling pathway have been observed in certain selection contexts and contribute to the resistance to agents that target hormonal regulation of the AR, including standard androgen deprivation therapy, antiandrogens such as enzalutamide, and androgen synthesis inhibitionwith abiraterone acetate.One such resistancemechanismis the synthesis of constitutively active AR variants lacking the canonical ligand-binding domain. This review focuses on the etiology, characterization, biological properties, and emerging data contributingto the clinical characteristicsofARvariants, andsuggests approaches to-full-length AR and AR variant biomarker validation, assessment, and systemic targeting in the clinic.

KW - Androgen receptor

KW - AR variants

KW - Castration resistant prostate cancer

KW - Epithelial to mesenchymal transition

KW - Metastasis

KW - Splice variants

UR - http://www.scopus.com/inward/record.url?scp=84905974623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905974623&partnerID=8YFLogxK

U2 - 10.1530/ERC-13-0470

DO - 10.1530/ERC-13-0470

M3 - Article

C2 - 24859991

AN - SCOPUS:84905974623

VL - 21

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 4

ER -